AKT1 and B-cell chronic lymphocytic leukemia: To confirm that idelalisib and GS-9973 effectively inhibit BCR mediated signaling, we evaluated phosphorylation of Akt and ribosomal S6 in CLL cells after treatment with idelalisib and GS-9973.